FBR Capital analyst William Tanner, Ph.D reiterated his Outperform rating and $198 price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) Monday ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE